TABLE 3.
Patient characteristics based on GPS, NLR, and BMI.
| Variables | GPS | NLR | BMI | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 0–1 | 2 | p‐value | Low (<5) | High (≥5) | p‐value | Low (<22.0) | High (≥22.0) | p‐value | |
| Patients (n) | 164 | 72 | 160 | 76 | 114 | 122 | |||
| Characteristics | |||||||||
| Sex | |||||||||
| Male/female | 130/34 | 59/13 | 0.72 | 126/34 | 63/13 | 0.49 | 84/30 | 105/17 | 0.02 |
| Median age at treatment (years) (range) | 68.5 (24–82) | 66.5 (34–81) | 0.19 a | 69 (37–82) | 65.5 (24–81) | 0.007 a | 68 (24–81) | 68 (37–82) | 0.75 a |
| Performance status (PS) | |||||||||
| 0–1/≥ 2 | 158/6 | 62/10 | 0.008 | 153/7 | 67/9 | 0.04 | 105/9 | 115/7 | 0.6 |
| Smoking history | |||||||||
| Yes/no | 141/23 | 68/4 | 0.07 | 141/19 | 68/8 | 0.83 | 100/14 | 109/13 | 0.83 |
| Intracranial metastases at initial treatment | |||||||||
| Yes/no | 37/127 | 21/51 | 0.32 | 35/125 | 23/53 | 0.19 | 27/87 | 31/91 | 0.76 |
| Liver metastases at initial treatment | |||||||||
| Yes/no | 9/155 | 3/69 | >0.99 | 7/153 | 5/71 | 0.53 | 3/111 | 9/113 | 0.13 |
| Bone metastases at initial treatment | |||||||||
| Yes/no | 51/113 | 37/35 | 0.003 | 51/109 | 37/39 | 0.014 | 44/70 | 44/78 | 0.78 |
| BMI (kg/m2) | |||||||||
| Median (range) | 22.8 (13.3–36.5) | 21.0 (15.6–28.6) | 0.0002 a | 22.7 (13.3–36.5) | 21.0 (15.1–28.8) | 0.0024 a | 20.1 (13.3–21.9) | 24.5 (22.0–36.5) | ‐ |
| Prior radiotherapy ‡ | |||||||||
| Yes/no | 38/126 | 20/52 | 0.51 | 28/132 | 30/46 | 0.0004 | 33/81 | 25/97 | 0.17 |
| Administration cycles of pembrolizumab plus platinum and pemetrexed | |||||||||
| Median (range) | 4 (1–5) | 4 (1–6) | 0.25 a | 4 (1–4) | 4 (1–6) | 0.021 a | 4 (1–6) | 4 (1–5) | 0.37 a |
| Administration cycles of maintenance therapy | |||||||||
| Median (range) | 4 (0–47) | 3 (0–51) | 0.09 a | 4 (0–47) | 2 (0–51) | 0.15† | 3 (0–51) | 4 (0–48) | 0.03 a |
| Laboratory data | |||||||||
| CRP (mg/dL) | 0.28 | 5.48 | <0.0001 a | 0.35 | 3.4 | <0.0001 a | 1.22 | 0.35 | 0.013 a |
| Albumin (g/dL) | 3.9 | 3 | <0.0001 a | 3.8 | 3.3 | <0.0001 a | 3.4 | 3.9 | <0.0001 a |
| Neutrophil (cells/μL) | 4288 | 6206 | <0.0001 a | 4159 | 7222 | <0.0001 a | 5200 | 4565 | 0.09 a |
| Lymphocyte (cells/μL) | 1411 | 1201 | 0.06 a | 1600 | 935 | <0.0001 a | 1195 | 1515 | 0.0039 a |
| Treatment response | |||||||||
| CR | 8 | 3 | 9 | 2 | 7 | 4 | |||
| PR | 75 | 35 | 77 | 33 | 48 | 62 | |||
| SD | 57 | 14 | 52 | 19 | 33 | 38 | |||
| PD | 21 | 17 | 20 | 18 | 23 | 15 | |||
| NE | 3 | 3 | 2 | 4 | 3 | 3 | |||
| Response rate (%) (95% CI) | 50.6 (43.0–58.1) | 52.7 (41.3–63.8) | 0.770 | 53.7 (46.0–61.2) | 46.0 (35.3–57.1) | 0.32 | 48.2 (39.2–57.3) | 54.0 (45.2–62.6) | 0.43 |
| Disease control rate (%) (95% CI) | 85.3 (79.0–90.0) | 72.2 (60.8–81.2) | 0.028 | 86.2 (79.9–90.8) | 71.0 (59.9–80.0) | 0.0071 | 77.1 (68.6–83.9) | 85.2 (77.7–90.5) | 0.13 |
Note: Fisher's exact test. Bold font indicates a statistically significant difference.
Abbreviations: BMI, body mass index; CI, confidence interval; CR, complete response; CRP, C‐reactive protein; GPS, Glasgow prognostic score; NE, not evaluated; NLR, neutrophil‐to‐lymphocyte ratio; PD, progressive disease; PR, partial response; SD, stable disease.
a
Welch's t‐test.
b
Including palliative radiotherapy and curative intent chemoradiotherapy.